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In searching for pharmacologic agents able to reduce
xenobiotic-induced skin irritation, we found that
cyclosporine A exacerbates the skin irritation
induced by tributyltin. We previously demonstrated
the involvement of interleukin-1a and tumor necro-
sis factor a in tributyltin-induced skin irritation.
Here, we show that cyclosporine A (28 mg per kg),
at a dose that results in systemic immunosuppres-
sion, potentiates tributyltin-induced skin irritation
through increased tumor necrosis factor a produc-
tion, associated with increased tributyltin-induced
activation of transcription factor nuclear factor kB in
cyclosporine-A-treated mice. On the other hand,
under the same experimental conditions, cyclospor-
ine A prevented the elicitation phase of oxazolone-
induced contact allergy, but was ineffective in
preventing benzalkonium-chloride-induced skin irri-
tation. Using a murine keratinocyte cell line (HEL30)
we demonstrated, also in vitro, that the cyclosporine
A potentiates tributyltin-induced nuclear factor kB
activation and cytokine production, this being pre-
ceded by an increase in cellular oxidative activity,
essential for nuclear factor kB activation, that is time
and dose (0.1±10 mM) dependent. This effect was not
exclusive to tributyltin but could be extended to
other mitochondrial poisons such as sodium
arsenate. It has been reported that cyclosporine A
binds to cyclophilins. An 18-mer antisense phosphor-
othioate oligodeoxynucleotide was used to target
mitochondrial cyclophilin D mRNA. After 24 h
exposure to the oligonucleotide, the amount of
cyclophilin D in the cells was decreased by 54% as
judged by Western blot analysis. Cyclophilin D sup-
pression prevented cyclosporine A potentiation of
tributyltin-induced cellular oxidative activity, indi-
cating the key role of the binding of cyclosporine A
to mitochondrial cyclophilin D in mediating this
effect. Key words: organitans/cyclophilin/mitochondria/
keratinocytes. J Invest Dermatol 117:1627±1634, 2001
D
epending on the country, dermatoses comprise 20%±
70% of all occupational diseases. Irritation of the skin
is important, and it is commonly thought to account
for approximately 60%±80% of the clinically recog-
nized cases of human contact dermatitis, most of the
remainder being allergic contact dermatitis (Wahlberg, 1996).
Occupational and accidental exposure to tributyltin (TBT), a
biocidal agent used mainly in wood preservation and marine
antifouling paints, results in skin and eye irritation, and severe
dermatitis has been reported after direct TBT contact with the skin
(reviewed by World Health Organization, 1990).
The biochemical mechanisms involved in skin irritation are
complex. Skin in¯ammatory reactions are under the control of a
network of cytokines and lipid mediators (Boss and Kapsenberg,
1993; Corsini and Galli, 1998). We have previously demonstrated
the involvement of interleukin-1a (IL-1a) (Corsini et al, 1996b)
and tumor necrosis factor a (TNF-a) (Corsini et al, 1997) in TBT-
induced skin irritation in the mouse. Both cytokines if injected into
the skin independently trigger cutaneous in¯ammation (Kupper,
1990). Furthermore, both IL-1 and TNF-a are functionally
relevant to a variety of in¯ammatory skin diseases, both in rodents
and in humans (Wake®eld et al, 1991; Groves et al, 1995; 1996;
Gniadecki, 1998). Inducible expression of cytokines is controlled
by the activity of transcription factors (Muegge and Durum, 1990).
In particular, nuclear factor kB (NF-kB) and activator protein-1/c-
jun (Rhoades et al, 1992) have been implicated in TNF-a and IL-
1a expression. We have shown earlier that TBT is able to induce,
both in vitro and in vivo, a dose-dependent NF-kB activation, which
is followed by cytokine production (Corsini et al, 1996a; 1997).
Furthermore, TBT skin edema and TNF-a production were
signi®cantly reduced by topical treatment with dexamethasone and
pentamidine, two anti-in¯ammatory agents, with the dexametha-
sone decreasing TBT-induced NF-kB activation (Corsini et al,
1997). Triorganotins affect mitochondrial activity, inhibiting ATP
synthesis, disturbing the proton gradient, and generating reactive
oxygen species (ROS), and induce mitochondrial swelling (Snoeij
et al, 1987; Marinovich et al, 1990; Corsini et al, 1996a). ROS are
involved in the activation of transcription factors, such as NF-kB
and AP-1, and in the production of cytokines (Baeuerle and
Henkel, 1994). We were able to demonstrate that TBT-induced
NF-kB activation and cytokine production are dependent on
mitochondria (Corsini et al, 1996a; 1998), depletion of which by
prolonged treatment with ethidium bromide resulted in a dramatic
reduction of TBT-induced NF-kB activation and IL-1a produc-
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tion. This indicates that mitochondria serve as mediators of the
effect of TBT on ROS generation.
In searching for other pharmacologic agents able to modulate
TBT-induced skin irritation, we found that cyclosporine A (CyA),
a potent immunosuppressant, exacerbates skin irritation induced by
TBT rather than preventing it. CyA is a lipophilic, cyclic fungal
undecapeptide that is extensively used as immunosuppressive agent
in the prevention of allograft rejection and in a variety of
autoimmune diseases (Kahan, 1989). CyA is also highly effective
in the treatment of psoriasis, atopic dermatitis, and many other
in¯ammatory dermatoses (Ellis et al, 1991; Berth-Jones, 1996;
Ruzicka, 1996). CyA was chosen because in vitro it inhibits
mitochondrial permeability transition-pore formation and subse-
quent mitochondrial swelling by displacing bound cyclophilin D
and decreasing the Ca2+ sensitivity of the pore (Grif®ths and
Halestrap, 1991; Savage et al, 1991; Broekemeier et al, 1992).
Because of this protective effect on mitochondria and the
importance of mitochondria in TBT toxicity, we examined the
effect of CyA on TBT-induced skin irritation.
MATERIALS AND METHODS
Chemicals Tributyltin chloride was obtained from Aldrich
(Steinhein, Germany), cyclosporine A was kindly provided by Novartis
(Basel, Switzerland), cremophor, benzalkonium chloride, 4-ethoxy-
methylene-2-phenyloxazol-5-one (oxazolone), and sodium arsenate from
Sigma (St. Louis, MO), and dichlorodihydro¯uorescein diacetate
di(acetomethyl ester) (DCFH) from Molecular Probes (Eugene, OR). All
reagents were purchased at the highest purity available. For the in vivo
studies CyA was dissolved in cremophor:ethanol (10:1; cremophor) and
TBT in acetone, whereas for the in vitro studies CyA and TBT were
both dissolved in dimethylsulfoxide (DMSO).
Animals Female BALB/C mice 9±12-wk-old (Charles River, Calco,
Italy) were used throughout these studies. Mice were randomized into
treatment groups, housed three to four per cage over wood-chip
bedding, and allowed food and water ad libitum. Before treatment mice
were quarantined for 2 wk and were acclimatized to a 12 h light±dark
cycle.
Animal exposure Animals (n = 3±4) were injected intraperitoneally
with 200 ml of CyA (11.4 or 28 mg per kg) or cremophor:ethanol (10:1)
as vehicle control 24 and 3 h before TBT or acetone treatment. This
schedule of treatment was chosen to guarantee a systemic distribution
and effect of CyA. Mice received different amounts (134±268 nmol) of
TBT dissolved in 10 ml of acetone on both sides of both ears or an equal
volume of acetone alone. The doses were chosen from data in the
literature (Middleton, 1982). Ears were treated on both sides to
maximize induction of cytokine production. At various times after
treatment, mice were sacri®ced, the increase in ear thickness was
measured with a micrometer, and the ears were removed. One ear was
used to determine the dry weights, measured after heating at 105°C for
24 h. The other ear was used either for histology or for the TNF-a
content of whole ear, determined in a skin homogenate prepared as
previously described (Corsini et al, 1997). For histology, ears were ®xed
in phosphate-buffered saline (PBS, pH 7.4) with 10% formalin,
dehydrated, and embedded in paraf®n. Hematoxylin±eosin-stained
sections were analyzed under light microscopy.
To assess the effect of CyA on benzalkonium-chloride-induced skin
irritation, mice were treated with CyA (28 mg per kg) as above
described, and then 10 ml of benzalkonium chloride or acetone was
applied on both sides of the ears. Animals were killed 24 h later and ear
skin thickness was measured.
To assess the effect of CyA on oxazolone-induced contact allergy,
mice were shaved on their dorsal surface and the following day sensitized
by topical application of 100 ml of 2% oxazolone dissolved in 4:1
acetone:olive oil mixture (AOO). Four days after sensitization, mice
were treated with CyA (28 mg per kg) as above described. On day 5
after CyA mice were challenged with 10 ml of 0.5% oxazolone by topical
Table I. CyA exacerbates TBT-induced TNF-a production in vivoa
Time (h)
Cremophor/acetone
(pg per mg dry weight)
CyA/acetone
(pg per mg dry weight)
Cremophor/TBT
(pg per mg dry weight)
CyA/TBT
(pg per mg dry weight)
1 0.5 6 0.1 0.6 6 0.1 1.9 6 0.1** 4.8 6 1.5**,§
2 0.7 6 0.1 0.7 6 0.1 2.5 6 0.9* 20.9 6 5.3**,§§
4 0.9 6 0.1 0.8 6 0.2 1.8 6 0.4* 4.0 6 0.5**,§§
24 1.0 6 0.2 1.1 6 0.2 1.0 6 0.2 1.1 6 0.2
aThree female BALB/C mice per group were injected intraperitoneally with cremophor or CyA 11.4 mg per kg body weight 18 and 3 h before topical application of
acetone or TBT 134 nmol. The animals were sacri®ced at different times thereafter. Total ear TNF-a (per mg dry weight) was measured as cytotoxicity against sensitive
L929 cells (Rosenthal et al, 1995). Results are expressed as mean 6 SD. Statistical analysis by Dunnett's test: *p < 0.05 and **p < 0.01 versus the relative control groups;
§p < 0.05 and §§p < 0.01 versus cremophor/TBT group.
Figure 1. CyA exacerbates TBT-induced skin irritation. Mice
were treated by intraperitoneal injection with CyA (28 mg per kg) or
cremophor:ethanol (cremophor) as vehicle control 24 and 3 h before
topical application of TBT (268 nmol) or acetone as vehicle control.
Skin thickness (A) and TNF-a content (B) were measured 2 h after
TBT application. (A) Inset shows the lymphoproliferative response to
ConA and PHA stimulation following CyA or vehicle treatment. Mean
6 SD (n = 3). Student's t test, *p < 0.05 versus vehicle control; §p
< 0.05 versus animals treated with TBT and cremophor. (B) Inset shows
the NF-kB activation 5 min after TBT application. Equal amounts
(5 mg) of nuclear extract were analyzed by EMSA, with a 32P-labeled
DNA probe detecting the binding activity of NF-kB.
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application to both sides of the right ear. AOO was applied to the left
ear as vehicle control. Immunologic responses to oxazolone were assessed
24 h after challenge by measuring the increase in skin thickness.
Assay for TNF-a TNF-a content was assayed by determining the
cytotoxicity of TNF-a against sensitive L929 cells, as previously
described (Rosenthal and Corsini, 1995). The results are expressed in pg
per mg dry tissue. TNF-a concentration was calculated against a
standard curve with known amounts of recombinant murine TNF-a
(R&D Systems).
Preparation of nuclear extracts and electrophoretic mobility shift
assay (EMSA) Nuclear extracts were prepared from chopped ear
skin as previously described (Corsini et al, 1997). The supernate
containing nuclear proteins was stored at ±80°C until used in the
EMSA. EMSA was performed as follows. Binding reaction mixtures
(20 ml) containing 5 mg protein of nuclear extract, 0.5 mg poly(dI-
dC).poly(dI-dC) (Sigma), and 10,000 cpm 32P-labeled probe in
binding buffer [10 mM HEPES pH 7.9, 50 mM NaCl, 1 mM
ethylenediamine tetraacetic acid (EDTA), 1 mM dithiothreitol, 10%
(vol/vol) glycerol, 1% Ficoll, and 0.2 mg per ml albumin] were
incubated for 30 min at room temperature before separation in a 7%
acrylamide gel in 1 3 Tris borate EDTA followed by
autoradiography. A double-stranded oligonucleotide containing the
binding site for NF-kB (5¢-GTCTCGCAATTCCCCTCTCTCAG-3¢)
was labeled with a-32P-dATP (Amersham, Buckinghamshire, U.K.)
using T4 polynucleotide kinase (Amersham). We have previously
characterized the speci®city of the probe used (Corsini et al, 1996a).
Lymphoproliferative assays Spleens were removed and single-cell
suspensions were prepared in culture medium. Aliquots containing
2 3 106 cells were added to 96-well ¯at bottom microtiter plates.
Figure 2. Hematoxylin and eosin staining of
ear following CyA and TBT treatment. Mice
were treated by intraperitoneal injection with
CyA (11.4 and 28 mg per kg) or
cremophor:ethanol (cremophor) as vehicle control
24 and 3 h before topical application of TBT
(268 nmol) or acetone as vehicle control for 2 h.
Scale bar: 50 mm.
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Lymphocytes were stimulated with either 2 mg per ml concanavalin A
(ConA; Boehringer Mannheim, Germany) or 1.2% of
phytohemagglutinin (PHA; Gibco, Piasley, U.K.). The blastogenic
response was determined by the ability of cells to incorporate 3H-
thymidine into DNA as described previously in detail (Smialowicz,
1995). Results are expressed as the stimulation index SI, calculated as
follows:
SI = (cpm)stimulated/(cpm)unstimulated
Cell culture and treatment Murine keratinocyte cell line HEL30
(kindly supplied by Dr. N.E. Fusenig, Cancer Research Center,
Heidelberg, Germany) was cultured as previously described (Corsini et al,
1994). Cells were mantained in RPMI 1640 medium (Sigma)
supplemented with 10% fetal bovine serum (Sigma), penicillin (100 U
per ml), and streptomycin (100 mg per ml) (medium) at 37°C in a 5%
CO2 humidi®ed incubator.
For the measurement of oxidative activity (see below) cells were
grown to con¯uence on sterile round glass slips (Knittel Glaser,
Germany) in a 24-well plate (Corning, NY). For the determination of
IL-1a content, con¯uent cells were treated for 1 h at 37°C with 0.3 ml
of medium containing CyA or DMSO as vehicle control and then TBT
(2.5 mM) dissolved in DMSO was added. The DMSO concentration in
the culture medium never exceeded 0.1%. After 24 h of incubation
monolayers were washed once with PBS and lyzed in 0.3 ml PBS
containing Triton X-100 (0.5%), and IL-1a was determined by enzyme-
linked immunosorbent assay (ELISA) (see below). To assess the effect of
CyA on TBT- or As-induced NF-kB activation, con¯uent cells in 60
mm Petri dishes were incubated at 37°C for 1 h with CyA (10 mM), and
then TBT (2.5 mM) or As (50 mM) was added for 30 min and nuclear
cell extracts were prepared as previously described (Corsini et al, 1996a).
To reduce cyclophilin D expression an 18-mer antisense oligonucleo-
tide (Primm, Milan, Italy) corresponding to nucleotides 561±578 in the
rat cyclophilin D sequence (Wood®eld et al, 1997) was utilized: 5¢-
TATTTTCTTCACAACATC-3¢ (antisense). As control, the sense com-
plement oligonucleotide was used. Both oligonucleotides contained
phosphorothioate linkages to limit degradation. Con¯uent cells were
treated for 24 h with 3 mM phosphorothioate oligonucleotide in culture
medium (Doyle et al, 1999) and then cyclophilin D immunoreactivity
and cellular oxidative activity were evaluated as described. The treatment
was not cytotoxic for the cells as assessed by lactated dehydrogenase
leakage (data not shown).
Western blot analysis For the immunoreactivity of cyclophilin D,
monolayers in a 60 mm Petri dish were washed once with PBS and
Figure 3. CyA acts via a mechanism that appears to involve
immunomodulation rather than mere nonspeci®c anti-
in¯ammatory effects. Mice were treated by intraperitoneal injection
with CyA (28 mg per kg) or cremophor:ethanol (cremophor) as vehicle
control 24 and 3 h before topical application of benzalkonium chloride
(1%) or challenged with oxazolone (0.5%) or vehicle control. Skin
thickness was measured 24 h after application. Mean 6 SD (n = 4). (A)
Effect of CyA on benzalkonium-chloride-induced skin irritation; (B)
effect of CyA on oxazolone-induced contact allergy. Student's t test, *p
< 0.05 versus vehicle control; §p < 0.05 versus animals treated with
oxazolone and cremophor.
Figure 4. Action of CyA and TBT on a murine keratinocyte cell
line. Cells were treated for 1 h with CyA (10 mM) or DMSO as vehicle
control and then TBT (2.5 mM) was added for 30 min for NF-kB
activation or for 24 h for IL-1a production, both released and cell-
associated. Mean 6 SD (n = 3). Student's t test, with *p < 0.05 versus
vehicle control, §p < 0.05 versus cells treated with TBT. Inset, NF-kB
activation. Lane 1, cells + DMSO; lane 2, cells + CyA; lane 3, cells
+ TBT; lane 4, cells + CyA + TBT. Equal amounts (5 mg) of nuclear
extract were analyzed by EMSA, with a 32P-labeled DNA probe
detecting the binding activity of NF-kB.
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scraped in PBS; after centrifugation, the pellet was lyzed in 100 ml of
homogenation buffer (50 mM Tris, 150 mM NaCl, 5 mM EDTA
pH 7.5, 0.5% Triton X-100, 50 mM phenylmethylsulfonyl ¯uoride, 2 mg
per ml aprotinin, 1 mg per ml pepstatin, and 1 mg per ml leupeptin) and
denatured in 100 ml of Laemmli sample buffer (Laemmli, 1970) for
5 min at 100°C. The protein content of the cell lysate was measured
using a commercial kit (Bio-Rad, Richmond, CA). Ten micrograms of
protein were then electrophoresed into a 12% sodium dodecyl sulfate
(SDS) polyacrylamide gel under reducing conditions. After
electrophoresis, the proteins were transferred to PVDF membrane
(Amersham, Little Chalfont, U.K.) in 20 mM Tris, 150 mM glycine,
20% methanol, 0.03% SDS. The cyclophilin D was visualized using a
cyclophilin D antiserum diluted at 1:500 as the primary antibody and
developed using enhanced chemiluminescence according to the
manufacturer's instruction (Amersham). Molecular weight references
were obtained by running one lane with prestained standard
(Amersham). The image of the immunoblotting was acquired with a
Nikon CCD video camera module. The optical density of the bands was
calculated and analyzed by means of the Image 1.47 program for digital
image processing (Wayne Rasband, Research Service Branch, NIMH,
NIH, Bethesda, MD).
Oxidative activity in living cells Con¯uent cells were washed once
with Hank's balanced salt solution without phenol red (HBSS)
containing 2% bovine serum albumin and were loaded with DCFH
10 mM (stained) or DMSO (unstained) for 1 h at 37°C in the presence
or absence of different concentrations of CyA (0.01±10 mM). Then cells
were washed once with HBSS and oxidative activity was assessed as
follows. Glass coverslips in quartz cuvettes containing 2 ml of HBSS
were treated with TBT (2.5 mM), sodium arsenate (50 mM), or DMSO
as vehicle control. ROS production was measured as DCFH oxidation
by the intensity of the emission of 525 nm ¯uorescence excited by
503 nm (Perkin Elmer LS 50B), at time 0 and 5, 15, and 30 min
following treatment both in stained and unstained cells. Results are
expressed as the change in ¯uorescence (in arbitrary units, AU)
calculated as follows:
AU = (Istained ± Iunstained)tx ± (Istained ± Iunstained)t0
where I represents the intensity of ¯uorescence.
ELISA IL-1a content was measured by a speci®c sandwich ELISA as
previously described (Corsini et al, 1996b). The limit of sensitivity for
this assay is 15 pg per ml. Results are expressed as pg per ml. Preliminary
Figure 5. CyA potentiates TBT-induced cellular oxidative activity
in live cells, as measured by DCFH oxidation. Con¯uent HEL30
cells were loaded for 1 h with 10 mM DCFH and treated with different
concentrations of CyA (0.1±10 mM) and then TBT (2.5 mM) or DMSO
as vehicle control was added for different times. (A) Effects 15 min after
TBT treatment; (B) time course of TBT-induced oxidative activity.
Mean 6 SD (n = 3). Dunnett's t test, *p < 0.05 versus vehicle control;
§p < 0.05 versus cells treated with TBT.
Figure 6. CyA potentiates sodium-arsenate-induced oxidative
activity, NF-kB activation, and IL-1a production in HEL30 cells.
(A) Oxidative activity and NF-kB activation following CyA (1 mM) and
sodium arsenate (50 mM). For cellular oxidative activity, con¯uent
HEL30 cells were loaded for 1 h with 10 mM DCFH and treated with
CyA (1 mM), and then As (50 mM) was added for 15 min. For NF-kB
activation, con¯uent cells were treated for 1 h with CyA (1 mM) or
DMSO as vehicle control and then As (50 mM) was added for 30 min.
Equal amounts (5 mg) of nuclear extract were analyzed by EMSA, with a
32P-labeled DNA probe detecting the binding activity of NF-kB. In lane
5 no nuclear extract was added (no sample), whereas in lane 6 to the
control nuclear extract a 100-fold excess of cold probe was used to
demonstrate NF-kB complex speci®city (cold). (B) Cell-associated IL-
1a. Con¯uent cells were treated for 1 h with CyA (1 mM) or DMSO as
vehicle control and then As (50 mM) was added for 24 h for IL-1a.
Mean 6 SD (n = 3). Dunnett's t test, *p < 0.05 versus vehicle control;
§p < 0.05 versus cells treated with As.
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studies showed that the maximum TBT or CyA concentrations tested
did not interfere with the ELISA.
Mitochondrial potential Rhodamine 123 (Sigma) was used to detect
changes in mitochondrial membrane potential following TBT and CyA
treatment in HEL30 cells (Ronot et al, 1986). Con¯uent cells in 24-well
plates were treated for 1 h at 37°C in the presence or absence of CyA
(1 mM). Then cells were treated with TBT (2.5 mM) or DMSO as
vehicle control. After 30 min at 37°C, culture medium was removed and
cells were loaded with rhodamine 123 10 mg per ml in medium for
30 min at 37°C. Cells were then rinsed, trypsinized, suspended in PBS,
and analyzed on a FACScalibur ¯ow cytometer (Becton Dickinson Italia,
Milan, Italy). Forward angle light scatter and integral green ¯uorescence
were measured for 10,000 events. The median channel ¯uorescence for
each histogram was determined by integral analysis with the CellQuest
software interfaced to the ¯ow cytometer and was used to compare the
effects of CyA on TBT-induced changes in the mitochondrial potential.
Statistical analysis All experiments were performed at least twice;
representative results are shown. Statistical signi®cance was determined
by Student's t test or Dunnett's multiple comparison test as indicated,
after ANOVA.
RESULTS
CyA exacerbates TBT-induced skin irritation Figure 1(A)
shows that CyA at a dose (28 mg per kg) that results in system
immunosuppression (inset), actually exacerbates TBT-induced skin
irritation, as measured by increased skin thickness 2 h after TBT
treatment. This could be explained by an increase, at the same time
point, of TBT-induced TNF-a production (Fig 1B). The increase
in TNF-a was associated with increased NF-kB activation (inset),
which is essential for TNF-a neosynthesis.
A similar effect has also been observed at lower CyA (11.4 mg
per kg) and TBT (134 nmol) doses. As shown in Table I, TNF-a
production by CyA + TBT follows the same kinetics as cremophor
+ TBT, but the effect is much more striking with CyA, which also
produced a signi®cantly greater increase in skin thickness at 24 h
than did cremophor (0.35 6 0.01 vs 0.31 6 0.01 mm, p < 0.05;
0.27 6 0.02 mm was the skin thickness in both acetone mice
groups). The potentiation of TBT-induced skin irritation by CyA
was con®rmed by histopathologic examination of ear skin, which
revealed a dose-related increase in neutrophil in®ltration following
CyA plus TBT treatment (Fig 2).
CyA prevents oxazolone-induced contact allergy but is
ineffective in benzalkonium-chloride-induced skin
irritation Under the same experimental conditions, CyA
(28 mg per kg) was ineffective in preventing benzalkonium-
chloride-induced skin irritation (Fig 3A), but effectively prevented
the elicitation phase of oxazolone-induced contact allergy
(Fig 3B). These data are consistent with the idea that CyA acts
via a mechanism that appears to involve immunomodulation rather
than mere nonspeci®c anti-in¯ammatory effects (Anderson, 1985),
and suggest that CyA-induced exacerbation of skin irritation is
speci®c for TBT.
Role of ROS and mitochondria in CyA-induced cytokine
production To better characterize and understand the effect of
CyA in TBT-induced skin irritation, we used a murine
keratinocyte cell line (HEL30) that has been reported to contain
cellular binding sites for CyA (Gschwendt et al, 1987). In this cell
line, similarly CyA potentiated TBT-induced NF-kB activation
(Fig 4, inset) as well as TBT-induced IL-1a production (Fig 4).
Under these experimental conditions, CyA alone did not affect
ROS production, NF-kB activation, or cytokine production.
We have previously shown that mitochondria-derived ROS play
a fundamental role in TBT-induced NF-kB activation and
cytokine production (Corsini et al, 1996a, 1997, 1998). Here we
demonstrated that CyA-induced NF-kB activation following TBT
treatment is preceded by a dose (0.1±10 mM) and time dependent
increased cellular oxidative activity (Fig 5A, B), which activates
NF-kB. This effect was shown by mitochondrial poisons other than
TBT such as sodium arsenate. Also in this case, we have previously
shown that mitochondria play a key role in ROS production, NF-
kB activation, and cytokine production (Corsini et al, 1999). As
shown in Fig 6, CyA potentiates arsenic-induced NF-kB acti-
vation (Fig 6A, inset), cellular oxidative activity (Fig 6A), and IL-
1a production (Fig 6B).
We have previously shown in HEL30 cells that TBT treatment is
associated with rapid mitochondrial swelling (Corsini et al, 1996a).
It is known that in vitro CyA is able to inhibit mitochondrial
permeability transition-pore formation and subsequent mitochon-
drial swelling (Grif®ths et al, 1991; Savage et al, 1991; Broekemeier
et al, 1992). Here, we demonstrated (Table II) that TBT 2.5 mM
reduced the median ¯uorescence to 70% of that observed for
control cells and CyA completely prevented TBT-induced changes
in mitochondrial membrane potential, preserving mitochondrial
integrity.
To further characterize the role of mitochondria, an 18-mer
antisense phosphorothioate oligodeoxynucleotide was designed to
target a translated region of the mitochondrial target of CyA
cyclophilin D mRNA. After 24 h exposure to the oligonucleotide,
the amount of cyclophilin D in the cells was decreased by
54% 6 14% (mean 6 SD of three independent experiments) as
judged by densitometric analysis of Western blots (Fig 7A).
Cyclophilin D suppression prevented CyA potentiation of TBT-
induced cellular oxidative activity (Fig 7B), indicating the key role
of the binding of CyA to mitochondrial cyclophilin D in mediating
this effect. Control sense oligonucleotide did not affect cyclophilin
D expression or cellular oxidative activity (Fig 7).
DISCUSSION
We found that CyA exacerbates TBT-induced skin irritation. At a
dose that results in system immunosuppression, CyA potentiated
TBT-induced skin irritation, as assessed by increased skin thickness
and histopathologic evaluation, but effectively prevented oxazo-
lone-induced contact allergy. This exacerbation could be explained
by increased TNF-a production in the mice treated with CyA
followed by TBT, which was associated with increased NF-kB.
Then, in a murine keratinocyte cell line in vitro CyA potentiated
TBT-induced NF-kB activation and cytokine production, this
being preceded by a dose- and time-dependent increased cellular
oxidative activity. This effect was also found for sodium arsenate, a
mitochondrial poison that, like TBT, stimulates mitochondria to
generate ROS, NF-kB, and IL-1a and induces mitochondrial
swelling (Corsini et al, 1999). A key role of the binding of CyA to
mitochondrial cyclophilin D in mediating cellular oxidative activity
by TBT was demonstrated.
The concentrations used in our in vitro studies (0.1±10 mM) are
similar to those achieved following exposure in vivo. In particular, it
has been demonstrated that skin biopsies obtained from psoriatic
patients treated for 7 d with a high dose of CyA (14 mg per kg per
d) had intracellular concentrations (based on tissue wet weight) of
2.8 mM (Ellis et al, 1991); with lower doses of CyA (3±7.5 mg per
Table II. CyA prevents TBT-induced changes in
mitochondrial membrane potentiala
Treatment Median channel ¯uorescence
Control DMSO 73.1 6 8.6
CyA 1 mM 78.7 6 4.4
TBT 2.5 mM 52.2 6 4.8*
CyA + TBT 69.8 6 2.3§§
aHEL30 cells were treated for 1 h at 37°C in the presence or absence of CyA
(1 mM). TBT (2.5 mM) or DMSO as vehicle control was then added. After
30 min at 37°C, culture medium was removed and cells were loaded with rhoda-
mine 123 10 mg per ml in medium for 30 min at 37°C. Cells were then analyzed
as described in the Materials and Methods. Mean 6 SD (n = 3). Statistical analysis by
Dunnett's test: *p < 0.05 versus control; §§p < 0.01 versus TBT.
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kg per d), intracellular epidermal CyA concentrations were around
1.0 mM (Cooper et al, 1992).
In this investigation we used TBT, a biocidal agent able to
induce skin and eye irritation in humans and rodents, because we
have previously characterized its molecular mechanism of action,
showing in vivo that both IL-1a and TNF-a play an important role
in TBT-induced skin irritation (Corsini et al, 1996b, 1997), and
that the production of these pro-in¯ammatory cytokines by TBT is
preceded by NF-kB activation. In vitro, we have shown the pivotal
role of mitochondria as the source of second messenger molecules
important for TBT-induced ROS generation, NF-kB activation,
and cytokine production (Corsini et al, 1996a, 1998).
CyA is a potent immunosuppressive agent, highly effective in the
treatment of several skin diseases, e.g., psoriasis and severe
refractory atopic dermatitis (Ellis et al, 1991; Berth-Jones, 1996).
Besides its effect on T cells, in vitro CyA is able to inhibit
mitochondrial permeability transition-pore formation and subse-
quent mitochondrial swelling by displacing bound cyclophilin D
and decreasing the Ca2+ sensitivity of the pore (Savage et al, 1991;
Grif®ths et al, 1991; Broekemeier et al, 1992). This protective effect
on mitochondria allows complete recovery of mitochondrial
membrane potential, and has been shown to prevent cell death in
several experimental models (Crompton et al, 1992; Ankarcrona et
al, 1996; Bernardi, 1996). Mitochondrial swelling is a common
feature after exposure to organotins (Snoeij et al, 1987), and we
have shown in HEL30 cells that TBT treatment is associated with
rapid mitochondrial swelling (Corsini et al, 1996a). This, together
with the protective role of CyA on mitochondria, led us to
investigate the potential anti-in¯ammatory effect of CyA on TBT-
induced skin irritation. Surprisingly, we found that CyA actually
exacerbates TBT-induced skin irritation.
We demonstrated that in its protective role CyA leads to
preservation of mitochondrial integrity, as assessed by rhodamine
132 uptake, so that when combined with mitochondrial poisons
CyA increases the generation of ROS and pro-in¯ammatory
cytokine production, resulting in an exacerbation of skin reactions.
Indeed, by reducing the expression of cyclophilin D, the
mitochondrial target of CyA, by antisense oligonucleotide treat-
ment, the potentiation of TBT-induced cellular oxidative activity
by CyA was completely prevented. In contrast, the antisense
oligonucleotide for cyclophilin A, the cytosolic isoform of rotamase
that also binds CyA, was ineffective (data not shown), further
supporting the key role of the binding of CyA to mitochondrial
cyclophilin D in mediating TBT-induced oxidative stress.
Taken together, these data may contribute to explain the variable
response to treatment of human skin diseases with CyA, with some
patients showing a paradoxically increased reactivity and some
showing no change (e.g., Ellis et al, 1991; Chawla et al, 1996). We
speculate in the nonresponsive patients a concomitant environ-
mental exposure to mitochondrial poisons or in the case of the use
of CyA in atopic dermatitis exposure to allergens somehow
affecting mitochondria. In this regard, it is important to remember
that the skin toxicants arsenic and organotins are also common
water contaminants. Nevertheless, even if our in vitro data did not
show any effect of CyA alone on the parameters considered, we
cannot exclude in patients undergoing CyA treatment for skin
diseases a different mitochondrial sensitivity to CyA itself, that may
result in ROS generation and pro-in¯ammatory cytokine
neosynthesis.
This work has been partially supported by UNIPRO.
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